natgillin/translations-raw huggingface dataset:
Hypoglykæmi (når Eperzan blev anvendt i kombination med insulin eller sulfonylurinstof)
Hypoglycaemia (when Eperzan is used in combination with insulin or sulphonylurea)
Hypoglykæmi (når Eperzan blev anvendt som monoterapi eller i kombination med metformin eller pioglitazon)
Hypoglycaemia (when Eperzan is used as monotherapy or in combination with metformin or pioglitazone)
Hypoglykæmi (ved brug sammen med sulfonylurinstof eller insulin)1
Hypoglycaemia (when used
Hypoglykæmi (ved samtidig anvendelse af SU eller insulin)b
Hypoglycaemia (when used with
Hypoglykæmi (ved samtidig anvendelse af sulfonylurinsto f eller insulin)b
Hypoglycaemia (when used with SU or insulin)b
Hypoglykæmi er en almindelig bivirkning (kan forekomme hos op til 1 ud af 10 brugere af dette lægemiddel), når dulaglutid bruges alene eller sammen med både metformin og pioglitazon.
Hypoglycaemia is common (may affect up to 1 in 10 people using this medicine) when dulaglutide is used alone or with both metformin and pioglitazone together.
Hypoglykæmi er en meget almindelig bivirkning (forekommer hos flere end 1 ud af 10 patienter).
Hypoglycaemia is a very commonly reported side effect (may affect more than 1 in 10 people).
Hypoglykæmi er en meget almindelig bivirkning (forekommer hos flere end 1 ud af 10 patienter).
Hypoglycaemia is a very commonly reported side effect (may affect more than 1 on 10 people.
Hypoglykæmi er en meget almindelige bivirkning.
Hypoglycaemia is a very common adverse reaction.
Hypoglykæmi i kombination med andre anti-hyperglykæmiske lægemidler
Hypoglycaemia when used in combination with other anti-hyperglycaemic medicinal product
Hypoglykæmi i kombination med andre anti-hyperglykæmiske lægemidler
Hypoglycaemia when used in combination with other anti-hyperglycaemic medicinal products
Hypoglykæmi i kombination med insulin eller et sulfonylurinstof
Hypoglycaemia in combination with insulin or sulphonylurea
Hypoglykæmi kan blive svær og kan medføre bevidstløshed og/eller kramper og kan medføre forbigående eller permanent nedsat cerebral funktion eller sågar død.
Hypoglycaemia can become severe and may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.
Hypoglykæmi kan forekomme, hvis dosis af Xultophy er større end nødvendigt.
Hypoglycaemia may occur if the Xultophy dose is higher than required.
Hypoglykæmi kan forekomme, hvis insulindosen er for høj i forhold til insulinbehovet.
Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement.
Hypoglykæmi kan opstå, hvis insulindosis er for høj i forhold til insulinbehovet.
Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement.
Hypoglykæmi kan opstå, såfremt insulindosis er for høj i forhold til insulinbehovet.
Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement.
Hypoglykæmi kan optræde som følge af for høj insulinaktivitet i forhold til fødeindtagelse og energiomsætning.
Hypoglycaemia may occur as a result of an excess of insulin acitivity relative to food intake and energy expenditure.
Hypoglykæmi kan udvikles og hypoglykæmimanifestationer (rysten, takykardi) kan maskeres af andre kliniske effekter af toksiciteten i betablokkere.
Hypoglycemia may develop and manifestations of hypoglycemia (tremor, tachycardia) may be masked by other clinical effects of beta-blocker toxicity.
Hypoglykæmi kan være forbundet med sløvhed, forvirring, hjertebanken, hovedpine, øget sved- tendens og opkastning.
Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
Hypoglykæmi kan være meget alvorligt og er meget almindeligt ved insulinbehandling (forekommer hos flere end 1 ud af 10 patienter).
Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people).
Hypoglykæmi kan være meget alvorligt og er meget almindeligt ved insulinbehandling (forekommer hos flere end 1 ud af 10 patienter).
Hypoglycaemia can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people).
Hypoglykæmi og hyperglykæmi
Hypoglyceamia and hyperglyceamia
Hypoglykæmi var den hyppigst rapporterede bivirkning for tripel-kombinationen linagliptin, metformin og insulin og forekom med sammenlignelig hyppighed, som når placebo og metformin blev kombineret med insulin (linagliptin plus metformin plus insulin 29,5 % og 30,9 % for placebo plus metformin plus insulin) og med en lav hyppighed af alvorlige episoder (1,5 % og 0,9 %).
When linagliptin and metformin were administered in combination with insulin, hypoglycaemia was the most frequently reported adverse event, but occurred at comparable rate when placebo and metformin were combined with insulin (linagliptin plus metformin plus insulin 29.5% and 30.9% in the placebo plus metformin plus insulin group) with a low rate of severe episodes (1.5% and 0.9%).
Hypoglykæmi var den hyppigst rapporterede bivirkning, når linagliptin og metformin blev administreret i kombination med et sulfonylurinstof (linagliptin plus metformin plus sulfonylurinstof 23,9 % og 16,0 % for placebo plus metformin plus sulfonylurinstof).
When linagliptin and metformin were administered in combination with a sulphonylurea, hypoglycaemia was the most frequently reported adverse event (linagliptin plus metformin plus sulphonylurea 23.9% and 16.0% in placebo plus metformin plus sulphonylurea).
Hypoglykæmi ved kombination med insulin eller et sulfonylurinstof
Hypoglycaemia in combination with insulin or sulphonylurea
Hypoglykæmi – Som for al insulinbehandling er den hyppigste bivirkning med EXUBERA hypoglykæmi (for lavt blodsukker).
Hypoglycaemia - As with all insulin therapy, the most common side effect with EXUBERA is hypoglycaemia (too low blood sugar).
Hypoglykæmi*
Hypoglycaemia
Hypoglykæmi*
Hypoglycemia
hypoglykæmi,
Psychiatric
Hypoglykæmi, der normalt er den hyppigst bivirkning ved insulinbehandling, kan opstå, hvis insulindosis er for høj i forhold til insulinbehovet.
Hypoglycaemia, in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
hypoglykæmi, hypokaliæmi, hyponatriæmi
hypoglycaemia, hypokalaemia, hyponatraemia
hypoglykæmi, hypoproteinæmi
hypoglycaemia, hypoproteinaemia
Hypoglykæmi, nedsat appetit, vægttab
Hypoglycaemia, decreased appetite, weight loss
Hypoglykæmi.
Hypoglycaemia
hypoglykæmi.
should be considered.
HypoglykæmiD (ved anvendelse sammen med SU)
HypoglycaemiaD (when used with
Hypoglykæmiincidensen var den samme på tværs af behandlingsgrupperne (placebo 1,4 %, linagliptin 5 mg 0 %, metformin 2,1 % og linagliptin 2,5 mg plus metformin 2 gange dagligt
The incidence of hypoglycaemia was similar across treatment groups (placebo 1.4%, linagliptin 5 mg 0%, metformin 2.1%, and linagliptin 2.5 mg plus metformin twice daily 1.4%).
Hypoglykæmirate (hændelser pr.
Rate of hypoglycaemia (events per PYE)
Hypoglykæmirate (pr. patientår med eksponering)
Hypoglycaemia Rate (per patient year of exposure)
Hypoglykæmirate (pr. patientår med eksponering)
Rate of hypoglycaemia (per patient year of exposure)
Hypoglykæmirate (pr. patientår med eksponering)
Rate of hypoglycaemia(per patient year of exposure)
Hypoglykæmisk aktivitet
Liprolog Basall
Hypoglykæmisk aktivitet
Liprolog Mix25 Liprolog Basal
Hypoglykæmiske stoffer
Hypoglycaemic agents
Hypoglykæmiske virkninger som resultat af den forstærkede hypoglykæmiske virkning kan opstå efter samtidig administration af glimepirid og f.eks.
Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following drugs is taken, for example:
Hypoglykæmi†
hypoglycaemia
Hypogonadis me
Hypersensitivit y
Hypogonadisme
Anxiety
Hypogonadisme
Hypogonadism
Hypogonadisme**
Hypogonadism
hypointense T1-læsioner
0.71 (0.55, 0.92)
hypointense T1-læsioner
hypointense lesions
hypokalcæmi
hypocalcaemia,
Hypokalcæmi
Hypocalcaemia.
Hypokalcæmi
Hypocalcarmia
Hypokalcæmi er en vigtig, identificeret risiko ved Zoledronsyre Teva ved de godkendte indikationer.
Hypocalcaemia is an important identified risk with Zoledronic acid Teva in the approved indications.
Hypokalcæmi Hypofosfatæmi
Hypocalcaemia
Hypokalcæmi Hypofosfatæmi
Hypocalcaemia Hypophosphataemia
Hypokalcæmi og andre forstyrrelser i knogle og mineralmetabolisme bør behandles effektivt før behandling med Ibandronsyre Teva initieres.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Ibandronic Acid Teva therapy.
Hypokalcæmi og andre forstyrrelser i knogle- og mineralmetabolisme skal behandles effektivt før behandling med Bondronat initieres.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Bondronat therapy.
Hypokalcæmi og andre forstyrrelser i knogle- og mineralmetabolisme skal behandles effektivt før behandling med Iasibon initieres.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Iasibon therapy.
Hypokalcæmi og andre forstyrrelser i knogle- og mineralmetabolisme skal behandles effektivt inden påbegyndelse af Bondronat-behandling ved metastatisk knoglesygdom.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Bondronat therapy for metastatic bone disease.
Hypokalcæmi og andre forstyrrelser i knogle- og mineralmetabolisme skal behandles effektivt inden påbegyndelse af Iasibon-behandling ved metastatisk knoglesygdom.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Iasibon therapy for metastatic bone disease.
Hypokalcæmi og andre forstyrrelser i knogle- og mineralmetabolisme skal effektivt behandles inden påbegyndelse af ibandronsyre-behandling ved metastatisk knoglesygdom.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting ibandronic acid therapy for metastatic bone disease.
hypokalcæmi)
(secondary to hypocalcaemia)
Hypokalcæmi*
Hypocalcaemi a
Hypokalcæmi*
Hypocalcaemia
Hypokalcæmi* Nedsat appetit
Hypocalcaemia* Decreased appetite
Hypokalcæmi, dehydrering, hyperuricæmi, tørst Hyperglykæmi, hypertriglyceridæmi§, øget appetit
Hypocalcaemia, dehydration, hyperuricemia, thirst Hyperglycaemia, hypertriglyceridaemia§, increased appetite
Hypokalcæmi.
Hypocalcaemia.
Hypokalcæmi‡ Hyperkolesterolæmib** Hypokaliæmi Appetitløshed Vægttab
Hypocalcaemia‡ Hypercholesterolaemiab** Hypokalaemia Decreased appetite Weight decreased
Hypokali- æmi
Hypokalaemia
Hypokaliæmi
administration
Hypokaliæmi
hypokalemia
Hypokaliæmi
Nausea
Hypokaliæmi (6,8 %) (G3/4: 2,0 %)
Hypokalaemia (6.8%) (G3/4: 2.0%)
Hypokaliæmi Anoreksi Hypomagnesiæmi
Hypokalaemia Anorexia Hypomagnesaemia
Hypokaliæmi eller hypomagnesiæmi skal korrigeres inden administration af Bosulif og monitoreres periodisk under behandlingen.
Hypokalaemia or hypomagnesaemia must be corrected prior to Bosulif administration and should be monitored periodically during therapy.
Hypokaliæmi eller hypomagnesæmi bør korrigeres, før HALAVEN påbegyndes, og disse elektrolytter skal overvåges periodisk i løbet af behandlingen.
Hypokalemia or hypomagnesemia should be corrected prior to initiating HALAVEN and these electrolytes should be monitored periodically during therapy.
Hypokaliæmi Hypofosfatæmi Hypokalcæmi Hyponatriæmi Hypomagnesiæmi Hyperurikæmi
Hypokalaemia Hypophosphatemia Hypocalcaemia Hyponatraemia Hypomagnesaemia Hyperuricaemia
Hypokaliæmi kan resultere i muskelkramper og/eller forstærke hjertearytmier forbundet med samtidig brug af digitalisglykosider eller visse anti-arytmiske lægemidler.
Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti- arrhythmic medicinal products.
Hypokaliæmi kan resultere i muskelspasmer og/eller forstærke hjertearytmier forbundet med samtidig brug af digitalis glykosider eller visse anti- arytmiske lægemidler.
Hypokalaemia may result in muscle spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain antiarrhythmic medicinal products.
Hypokaliæmi kan resultere i muskelspasmer og/eller forstærke hjertearytmier forbundet med samtidig brug af digitalisglykosider eller visse anti- arytmiske lægemidler.
Hypokalaemia may result in muscle spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain antiarrhythmic medicinal products.
Hypokaliæmi kan ved samtidig brug af digitalisglykosider eller visse antiarytmika resultere i muskelkramper og/eller accentueret arytmi.
Hypokalaemia may result in muscle spasms and/or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti- arrhythmic medicinal products.
Hypokaliæmi kan ved samtidig brug af digitalisglykosider eller visse antiarytmika resultere i muskelkramper og/eller accentueret arytmi.-
Hypokalaemia may result in muscle spasms and/or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.
Hypokaliæmi og hypomagnesiæmi skal korrigeres før administration af en 5- HT3-antagonist.
Hypokalemia and hypomagnesemia should be corrected prior to 5-HT3-antagonist administration.
Hypokaliæmi og quinidin havde additive / supraadditive virkninger in vitro, mens potenseringen var åbenbar med sotalol.
Hypokalaemia and quinidine had additive/supra- additive effects in vitro while potentiation was evident with sotalol.
Hypokaliæmi*
Hypokalaemia
Hypokaliæmi*, unormal blodglucose*, hyponatriæmi*, diabetes mellitus*, væskeretention
Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention
hypokaliæmi,
hypokalaemia,
hypokaliæmi, forhøjede lipider, appetitforstyrrelser (herunder anorexi), hyperuricaemia
Hypokalaemia, lipids increased, appetite disorders (including anorexia), hyperuricaemia
Hypokaliæmi, hyperglykæmi,
Loss of libido
Hypokaliæmi, hypernatriæmi eller Na⁺/K⁺-forhold > 32: Nedsæt dosis af Zycortal.
Hypokalaemia, hypernatremia or Na⁺/K⁺ ratio > 32: Decrease the Zycortal dose.
hypokaliæmi, hypomagnesæmi, hypokalcæmi
hypokalaemia, hypomagnesaemia, hypocalcaemia
hypokaliæmi1
Common
Hypokaliæmi3
Hypokalaemia3
Hypokaliæmi3, 5
hypokalaemia3, 5
Hypokaliæmi; nedsat appetit
Hypokalaemia; Decreased appetite
Hypokaliæmid
Hypokalaemiad
Hypokalkæmi
Hypocalcaemia
Hypokalkæmi og andre forstyrrelser i knogle- og mineralstofskiftet bør behandles effektivt før behandling med Ibandronsyre Sandoz initieres.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Ibandronic acid Sandoz therapy.
Hypokalkæmi**
Hypocalcaemia
Hypokalæmi
Hypokalemia
Hypokalæmi er forbundet med CKD, telmisartan påvirker imidlertid ikke kaliumekskretionen som påvist ved kliniske feltforsøg med katte.
Hypokalemia is associated with CKD, however telmisartan does not affect potassium excretion, as shown in the clinical field trial in cats.
Hypokalæmi Nedsat appetit Hyperuricæmi*
Hypokalaemia Decreased appetite Hyperuricaemia
Hypokalæmi, forhøjet alkalisk fosfatase, vægtøgning
Otitis media, tinnitus, hyperacusis, earache
Hypokromasi, megaloblastær anæmi
Anaemia megaloblastic, hypochromasia
Hypokromisk anæmi
Leukopaenia, anaemia, thrombocytopaenia
hypoksi
hypoxia
Hypoksi
Rectal haemorrhage
Hypoksi, hoste, dyspnø
Hypoxia, cough, dyspnoea
Hypoksi, takypnø, bronkospasmer, hoste
Hypoxia, tachypnoea, bronchospasm, cough
hypomagne- siæmi, alvorlig hypomagne- siæmi kan korrelere med hypo- calcæmi; hypomagne- siæmi kan også føre til hypokaliæmi
hypomagne- saemia; severe hypomagne- saemia can correlate with hypocalcae- mia; hypomagne- saemia may also result in hypokalaem- ia
Hypomagnesiæmi (2,8 %) (G3/4: 0,3 %)
Hypomagnesaemia (2.8%) (G3/4: 0.3%)
Hypomagnesiæmi; hypoglykæmi; hypoalbuminæmi; fejlernæring^;
Hypomagnesaemia; Hypoglycaemia; Hypoalbuminaemia; Malnutrition^;
hypomenorrhoe a, bryst hævelse, galaktoré, uterine spasmer, præmenstruelt syndrom, større bryster, dyspareuni, vulvovaginal tørhed
hypomenorrhoea, breast swelling, galactorrhoea, uterine spasm, premenstrual syndrome, breast mass, dyspareunia, vulvovaginal dryness
hyponatremi, hyperkaliæmi, hypofosfatæmi, anoreksi
hyponatraemia, hyperkalaemia, hypophosphataemia, anorexia
Hyponatriæ mi
Hyponatraemia
Hyponatriæmi Anoreksi Vægttab Vægtøgning
Hyponatremia Anorexia
Hyponatriæmi er indberettet som en bivirkning hos 1,2 % af de patienter, der fik Zebinix.
Hyponatraemia has been reported as an adverse reaction in 1.2% of patients treated with Zebinix.
Hyponatriæmi herunder tilfælde med serum-natriumværdier under 110 mmol/l, er blevet rapporteret efter indgivelse af ARICLAIM.
Hyponatraemia has been reported when administering ARICLAIM, including cases with serum sodium lower than 110 mmol/l.
Hyponatriæmi kan skyldes et syndrom med uhensigtsmæssig sekretion af anti-diuretisk hormon (SIADH).
Hyponatraemia may be due to a syndrome of inappropriate anti- diuretic hormone secretion (SIADH).
Hyponatriæmi og hypochloræmisk alkalose
Hyponatraemia and hypochloraemic alkalosis
Hyponatriæmi og hypokloræmisk alkalose
Hyponatraemia and hypochloraemic alkalosis
hyponatriæmi, alkalose, hypofosfatæmi, tumorlysesyndrom, hypokalcæmid
hyponatremia, alkalosis, hypophosphatemia, tumour lysis syndrome, hypocalcaemiad
Hyponatriæmi, hyperkalcæmi, symptomatisk hyperurikæmi og refraktorisk hypokaliæmi.
Hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia and refractory hypokalaemia.
Hyponatriæmi, hyperkalcæmi, symptomatisk hyperurikæmi og refraktær hypokaliæmi.
Hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia and refractory hypokalaemia.
Hyponatriæmia
Hyponatraemiaa
Hyponatræmi, hypomagnesæmi
Hyponatraemia, Hypomagnesae- mia
Hypophosphatasi
What is hypophosphatasia
Hypophosphatasi er en sjælden, alvorlig og muligvis dødelig genetisk sygdom, forårsaget af mutation(er) i genet, der koder for vævsuspecifik basisk fosfatase, med tab af funktion som følge.
Hypophosphatasia is a rare, severe, and potentially fatal, genetic disorder caused by loss-of-function mutation(s) in the gene encoding tissue non-specific alkaline phosphatase.
Hypophosphatæmi
Hypophosphataemia
hypophosphatæmi1
dizziness
Hypopig
Hypo- pigmentation
Hypopigmentering af huden
Skin hypopigmentation
hypopituitarisme (herunder hypofysitis)c, hypotyroidismec
hypopituitarism (including hypophysitis)c, hypothyroidismc
Hypopituitarisme Hypogonadisme Hypotyroidisme
Hypopituitarism Hypogonadism Hypothyroidism
Hyposmi*, Somnolens*
Hyposmia*, Somnolence
Hypotension
Rash generalised
Hypotension (fald i blodtryk)
Hypotension (decrease in blood pressure)
Hypotension (G3/4:
Hypotension
Hypotension (G3/4: 0 %);
Hypotension (G3/4: 0%);
Hypotension (G3/4: 0%);
Hypotension (G3/4: 0%)
Hypotension (G3/4: 0,7 %)
Hypotension
Hypotension (G3/4: 0,7 %)
Hypotension (G3/4: 0.7%)
Hypotension (G3/4: 0,7 %)
Lymphoedema
Hypotension (G3/4: 0,7%)
Hypotension (G3/4: 0.7%)
Hypotension (hypotension, blodtrykket er faldet) Rødmen (rødmen, hedeture) Hypertension (hypertension, accelereret hypertension)
Hypotension (hypotension, blood pressure decreased) Flushing (flushing, hot flush) Hypertension (hypertension, accelerated hypertension)
Hypotension (lavt blodtryk)
Hypotension (low blood pressure)
Hypotension (nogle af patienterne havde underliggende risikofaktorer)
Hypotension (some of the patients had underlying risk factors)
Hypotension blev ikke observeret, når der var et tidsinterval på 6 timer mellem administration af 5 mg vardenafil og terazosin.
Hypotension was not observed when vardenafil 5 mg and terazosin administration was separated by 6 hours.
Hypotension hos volumen- og/eller saltdepleterede patienter
Hypotension in volume- and /or salt-depleted patients
hypotension i hvile (blodtryk < 90/50 mmHg) eller hypertension (blodtryk > 170/100 mmHg)
Patients with resting hypotension (blood pressure < 90/50 mmHg) or hypertension (blood pressure > 170/100 mmHg);
Hypotension kan forekomme hos et lille antal patienter (vernakalant 7,6%, placebo 5,1%).
Hypotension can occur in a small number of patients (vernakalant 7.6%, placebo 5.1%).
Hypotension kan forekomme i begyndelsen af behandlingen, specielt hvis pramipexol optitreres for hurtigt.
Hypotension may occur at the beginning of
Hypotension rapporteret som alvorlig bivirkning eller førende til seponering af lægemidlet forekom hos patienter med venstresidig hjerteinsufficiens, efter de havde fået BRINAVESS, hos 2,9% af patienterne sammenlignet med 0% for placebo.
Hypotension reported as a serious adverse experience or leading to medicinal product discontinuation occurred in CHF patients following exposure to BRINAVESS in 2.9% of these patients compared to 0% in placebo.
Hypotension rapporteret som alvorlig bivirkning eller førende til seponering af medicinen forekom hos patienter med venstresidig hjerteinsufficiens, efter de havde fået BRINAVESS, hos 2,9% af patienterne sammenlignet med 0% for placebo.
Hypotension reported as a serious adverse experience or leading to medicine discontinuation occurred in CHF patients following exposure to BRINAVESS in 2.9% of these patients compared to 0% in placebo.
Hypotension var ikke observeret, når administrationen af 5 mg vardenafil og terazosin blev separeret med 6 timer.
Hypotension was not observed when vardenafil 5 mg and terazosin administration was separated by 6 hours.
Hypotension*, ortostatisk hypotension*
Hypotension*, Orthostatic hypotension
Hypotension*, ortostatisk hypotension, hypertension*
Hypotension*, Orthostatic hypotension, Hypertension
Hypotension,
Hypotension, Hot
Hypotension, der kræver behandling med intravenøse inotrope stoffer
Hypotension requiring treatment with intravenous inotropic agents
hypotension, flebitis
hypotension, phlebitis
Hypotension, hedeture/blussen
Hypotension, Flushing
Hypotension, hypertension, diastolisk hypertension, svingende blodtryk
Hypotension, hypertension, diastolic hypertension, blood pressure fluctuations
Hypotension, hypertension, ekkymose^
Colitis, Caecitis
Hypotension, hypertension, ekkymose^
Hypotension, Hypertension, Ecchymosis^
Hypotension, hypertension, synkope, rødme
Hypotension, hypertension, flushing
hypotension, ortostatisk hypotension
hypotension, orthostatic hypotension
hypotension, ortostatisk hypotension, rødmen
hypotension, orthostatic hypotension, flushing
hypotension, Raynauds syndrom, kolde hænder og fødder
hypotension, raynaud’s phenomenon, cold hands and feet
hypotension, Raynauds syndrom, kolde hænder og fødder
hypotension, Raynaud’s phenomenon, cold hands and feet.
hypotension, rødmen, hedeture
hypotension, flushing, hot flush
hypotension, synsforstyrrelser og
hypotension, visual changes, and
Hypotension, thrombophlebitis, rødme
Hypotension; thrombophlebitis; flushing
hypotension, tromboflebitis
hypotension, thrombophlebitis
Hypotension, vaskulit
Hypotension, Vasculitis
hypotension, vaskulitis
hypotension, vasculitis
Hypotension-patienter med hypovolæmi
Hypotension - Volume-depleted patients
Hypotension-patienter med hypovolæmi
Hypotension Volume-depleted patients
Hypotension1,4
Hypotension1, 4
hypotension2
Syncope2 Hypertension3,7
Hypotension3
Hypotension3,
Hypotension; Hypertension; Hæmoragi
Hypotension; Hypertension; Haemorrhage
Hypotensionh
Pyrexia
hypotermi, kulderystelser, forhøjet kropstemperatur, tørst, abstinens-
hypothermia, chills, body temperature increased, thirst, drug withdrawal
hypotermi, nekrose på injektionsstedet, sår på injektions- stedet
body temperature decreased, injection site necrosis, injection site ulcer
Hypotermic, nedsat kropstemperaturc,
hypothermiac, body
Hypotermic, nedsat kropstemperaturc,
pulmonary congestion
Hypotesen er, at en langsommere clearance af det radioaktive lægemiddel kan bidrage til retentionen i den hvide substans, idet den regionale cerebrale blodperfusion i den hvide substans er mindre en halvt så stor som den kortikale.
It is hypothesized that slower clearance of the radiopharmaceutical may contribute to white matter retention since regional cerebral blood flow in white matter is less than half of that of cortex.